SCHEMBL16676558

SCHEMBL16676558

O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)SCCS(=O)(=O)c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UBASH3B Q8TF42 1/20 0.68
▸ F11 P03951 3/20 0.45
▸ TACR1 P25103 3/20 0.43
▸ CCKBR P32239 1/20 0.42
▸ PPARG P37231 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ ITGB2 P05107 1/20 0.39
▸ ICAM1 P05362 1/20 0.39
▸ ITGAL P20701 1/20 0.39
▸ KLKB1 P03952 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16666864 0.87 UBASH3B (0.74) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL29868847 0.87 UBASH3B (0.74) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL16676563 0.86 UBASH3B (0.72) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL29868810 0.86 UBASH3B (0.72) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL16666448 0.86 UBASH3B (0.69) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL16666450 0.86 UBASH3B (0.69) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL16676584 0.85 UBASH3B (0.72) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL16676557 0.85 UBASH3B (0.72) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL16667576 0.85 UBASH3B (0.71) UBASH3BF11TACR1CCKBRPPARG
SCHEMBL23280196 0.84 UBASH3B (0.70) UBASH3BF11TACR1CCKBRPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865669-B1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF SAMJIN PHARM CO LTD (KR) 2021-04-28 — — EP disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF REV1, GRPR, SI UBASH3B 2690/4885F11 1844/4885TACR1 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback